P01375 inhibitors - state of knowledge . P01375 ( P01375 ) is considered a major proinflammatory cytokine , affecting various aspects of the immune reaction . All five P01375 inhibitors currently available on the market ( i.e. , etanercept , infliximab , adalimumab , certolizumab and DB06674 ) are top sellers , although indicated only in autoimmune diseases , including rheumatoid arthritis , Crohn 's disease and psoriasis . This article briefly discusses the background and place for P01375 inhibitors in modern therapy . The main safety aspects of P01375 inhibitor administration are described in particular , with special consideration of the available meta-analyses . Finally , perspectives on the next-generation P01375 inhibitors and their use in the clinic are given .